A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI community,
We would like to wish you a prosperous year heading into 2023. We ended 2022 with a number of exciting developments on the FAPI front. SOFIE served as the major sponsor for the Theranostics FAP Summit, an exceptional global virtual event led by the ICPO Foundation. In addition, the FDA granted SOFIE’s IND for [18F]FAPI-74 a “may proceed letter” to move into a Phase 2 study in Gastrointestinal Cancers. Five clinical sites have been identified in various stages of readiness for study launch and we expect the first site to be activated by the end of Q1, 2023.
At SOFIE we also look forward to continuing to build relationships with academic and industry leaders. Learn more below about our exciting partnership with Yantai LNC Biotechnology.
We hope you enjoy this newsletter and welcome your feedback on how we can better keep you informed.
SOFIE will be supporting colleagues at Yantai LNC Biotechnology where [68Ga]FAPI-46 PET will be used as a companion diagnostic to screen subjects and assess therapeutic effect in their study of 177Lu-LNC1004 Injection as a FAP therapeutic intervention. Yantai obtained access to [68Ga]FAPI-46 through a letter of cross reference to SOFIE Biosciences’ IND along with corresponding precursor and reference standard for use.
FAPI CLINICAL DEVELOPMENT HIGHLIGHTS
Each newsletter will feature recent FAPI publications.
Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
J Nucl Med. 2022 Nov 17
Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls
J Nucl Med. 2022 Nov 17
In case you missed it…FIRST EVER THERANOSTICS FAP SUMMIT HELD NOV 2022
SOFIE had the privilege to serve as the major sponsor for the International Centers for Precision Oncology (ICPO) Foundation’s all-virtual Theranostics FAP Summit, “Targeting the Tumor Microenvironment and Beyond” held November 4-5, 2022. This was the first event of its kind on FAP as a target.
Thirty speakers primarily from academia and industry presented on an array of topics ranging from FAP history to diagnostic and therapeutic applications and patient advocacy. Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, presented “FAPI Clinical Development Updates”, to a global audience of attendees across 35 countries.
Highlights of the summit can be found here.